Palatin Technologies Inc : PTN

PTN

Stock Data

$20.23

$0.02 (0.10%)

Asset Type

Common Stock

Exchange

AMEX

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Palatin Technologies, Inc., a specialty biopharmaceutical company, develops targeted receptor-specific therapies for the treatment of various diseases in the United States. The company is headquartered in Cranbury, New Jersey.

All PTN Articles

1 Article

Lee Jackson | Dec 3, 2025 at 8:15 AM EST

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day…

Palatin Technologies Inc : PTN

PTN

$20.23

All PTN Articles

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Palatin Technologies Inc : PTN

PTN

$20.23

All PTN Articles

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026